Expert Interview
Exploring the recent FDA approval of DAWNZERA (donidalorsen) from Ionis Pharmaceuticals and ANDEMBRY® (garadacimab-gxii) from CSL for patients with hereditary angioedema
Ticker(s): IONS, CSLLYInstitution: Allergy & Asthma Specialists of Dallas
- Board certified Internist and Allergist in private practice in Dallas, Texas. Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School and teaches at Parkland Memorial and Presbyterian Hospitals in Dallas.
- Follows 140 type 1 and 2 patients with HAE.
- Member of the U.S. Hereditary Angioedema Association and on the panel responsible for the HAWK, ICON and WAO hereditary angioedema consensus documents.
What are your thoughts on DAWNZERA’s mechanism of action, which reduces the production of plasma prekallikrein?
Added By: emily_adminWhat are your thoughts on ANDEMBRY's mechanism of action, which targets factor XIIa?
Added By: emily_adminWhat impact do you think DAWNZERA and ANDEMBRY will have on the treatment space for hereditary angioedema?
Added By: emily_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
